HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Hanley, M. J. Articles by Kenna, G. A. Search for Related Content PubMed PubMed Citation Articles by Hanley, M. J. Articles by Kenna, G. A.

MICHAEL J. HANLEY, PHARM.D., is a graduate student, Tufts University, Boston, MA; at the time of writing he was Pharm.D. candidate, University College of Pharmacy, Kingston, RI. GEORGE A. KENNA, PH.D., B.S.PHARM., is Assistant Professor of Psychiatry and Human Behavior (Research), Center for Alcohol and Addiction Studies (CAAS), Brown University, Providence, RI; at the time of writing he was Postdoctoral Fellow in Community Health, CAAS, Brown University.

Address correspondence to Dr. Kenna at the Center for Alcohol and Addiction Studies, Box G-S121-4, Brown University, Providence, RI 02803 (george_kenna{at}Brown.edu).

Purpose. The use of quetiapine as a drug to treat various substance use disorders as well as a drug of abuse is examined. Summary. Quetiapine’s effectiveness in treating schizophrenia and bipolar disorder is well-known; however, growing evidence has indicated that it may be useful in the treatment of various substance use disorders. Small-scale studies have been conducted to investigate the potential benefit of quetiapine in patients dependent on alcohol, cocaine, and amphetamines. The results of these two studies provide some evidence that quetiapine may benefit patients diagnosed with a mental illness who are also dependent on cocaine, amphetamines, or both, though more rigorous studies are needed. An unforeseen use of antipsychotics, specifically quetiapine, as drugs of abuse has emerged. Since antipsychotics are not classified as controlled substances, the majority of clinicians may not consider the diversion of antipsychotics for recreational purposes, but evidence of this is increasing, particularly in incarcerated individuals. Intravenous quetiapine abuse was first reported in the literature in 2005. Although most cases of quetiapine abuse have been reported in the correctional setting, inappropriate quetiapine use within the community has been documented. Thus far, all of the documented cases have involved patients with a prior history of substance abuse. Clinicians must be cognizant of the potential for quetiapine as a treatment for substance use disorders and as a drug of abuse. Conclusion. Quetiapine is a promising treatment for substance use disorders alone or combined with other psychiatric diagnoses, such as bipolar disorder and schizophrenia. Quetiapine abuse has also been documented, particularly in the correctional setting. Index terms: Alcohols, ethyl; Amphetamines; Antipsychotic agents; Cocaine; Drug abuse; Quetiapine; Toxicity